FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234002803> ?p ?o ?g. }

• W4234002803 endingPage "19" @default.
• W4234002803 startingPage "SCI" @default.
• W4234002803 abstract "Abstract Abstract SCI-19 The coagulation system is critical for limiting blood loss at a site of injury (hemostasis), but may also contribute to thrombotic disease. The model of a coagulation balance represents these two sides of the same coin. Thrombosis may occur in the venous or arterial circulation, causing pulmonary embolism or myocardial infarction and stroke, collectively the most common causes of death in the developed world. Recent data from genetically altered mouse models have challenged the dogma of a coagulation balance. Deficiency of coagulation factor XII (Hageman factor), a serine protease, which initiates the intrinsic pathway of coagulation, severely impairs thrombus formation but is not associated with any excessive bleedings in humans or in mice. Targeting factor XII protects from occlusive disease in experimental animal models. Individuals with hereditary deficiency in the factor XII substrate factor XI are largely protected form ischemic stroke and deep-vein thrombosis. These findings indicate that fibrin-forming mechanisms, which operate during pathologic thrombus formation, involve pathways distinct from those proceeding during normal hemostasis. As the factor XII-driven contact system selectively contributes to thrombosis, but not to hemostasis, inhibition of the system offers novel anticoagulation strategies associated with minimal or no bleeding risk. In contrast to factor XII deficiency states, a single missense mutation (Thr328Lys) in the coagulation protein is associated with a life-threatening swelling disease, hereditary angioedema type III. Pharmacological factor XII inhibitors interfered both with pathological thrombosis and edema formation suggesting broad medical implications. Factor XII is activated in vivo by platelet-released inorganic polyphosphate, a linear polymer of 60–100 phosphate residues that directly bound to the coagulation factor. Polyphosphates-driven factor XII activation triggered release of the inflammatory mediator bradykinin. Polyphosphates increased vascular permeability and induced skin edema formation in mice and animals deficient in factor XII or bradykinin receptors were resistant to polyphosphates-induced leakage. Polyphosphates were procoagulant via the intrinsic pathway of coagulation. Ablation of intrinsic coagulation pathway proteases factors XII and XI protected mice from polyphosphate-triggered lethal pulmonary embolism. Targeting polyphosphates with phosphatases interfered with procoagulant activity of activated platelets and blocked platelet-induced thrombosis in mice. Addition of polyphosphates restored defective plasma clotting of Hermansky-Pudlak Syndrome patients, who platelet lack storage organelles for polyphosphates. The data identify polyphosphates as the endogenous activator of factor XII having fundamental roles in platelet-driven proinflammatory and procoagulant disorders. Disclosures: No relevant conflicts of interest to declare." @default.
• W4234002803 created "2022-05-12" @default.
• W4234002803 creator A5072970827 @default.
• W4234002803 date "2010-11-19" @default.
• W4234002803 modified "2023-10-01" @default.
• W4234002803 title "In Vivo Roles for Factor XII" @default.
• W4234002803 doi "https://doi.org/10.1182/blood.v116.21.sci-19.sci-19" @default.
• W4234002803 hasPublicationYear "2010" @default.
• W4234002803 type Work @default.
• W4234002803 citedByCount "0" @default.
• W4234002803 crossrefType "journal-article" @default.
• W4234002803 hasAuthorship W4234002803A5072970827 @default.
• W4234002803 hasConcept C126322002 @default.
• W4234002803 hasConcept C142724271 @default.
• W4234002803 hasConcept C186738567 @default.
• W4234002803 hasConcept C203014093 @default.
• W4234002803 hasConcept C2777167447 @default.
• W4234002803 hasConcept C2778382381 @default.
• W4234002803 hasConcept C2778589496 @default.
• W4234002803 hasConcept C2780868729 @default.
• W4234002803 hasConcept C2781362458 @default.
• W4234002803 hasConcept C54173615 @default.
• W4234002803 hasConcept C71924100 @default.
• W4234002803 hasConceptScore W4234002803C126322002 @default.
• W4234002803 hasConceptScore W4234002803C142724271 @default.
• W4234002803 hasConceptScore W4234002803C186738567 @default.
• W4234002803 hasConceptScore W4234002803C203014093 @default.
• W4234002803 hasConceptScore W4234002803C2777167447 @default.
• W4234002803 hasConceptScore W4234002803C2778382381 @default.
• W4234002803 hasConceptScore W4234002803C2778589496 @default.
• W4234002803 hasConceptScore W4234002803C2780868729 @default.
• W4234002803 hasConceptScore W4234002803C2781362458 @default.
• W4234002803 hasConceptScore W4234002803C54173615 @default.
• W4234002803 hasConceptScore W4234002803C71924100 @default.
• W4234002803 hasIssue "21" @default.
• W4234002803 hasLocation W42340028031 @default.
• W4234002803 hasOpenAccess W4234002803 @default.
• W4234002803 hasPrimaryLocation W42340028031 @default.
• W4234002803 hasRelatedWork W12932324 @default.
• W4234002803 hasRelatedWork W15822282 @default.
• W4234002803 hasRelatedWork W15890236 @default.
• W4234002803 hasRelatedWork W17434352 @default.
• W4234002803 hasRelatedWork W2034222 @default.
• W4234002803 hasRelatedWork W2152716 @default.
• W4234002803 hasRelatedWork W3626975 @default.
• W4234002803 hasRelatedWork W415215 @default.
• W4234002803 hasRelatedWork W5175350 @default.
• W4234002803 hasRelatedWork W5532229 @default.
• W4234002803 hasVolume "116" @default.
• W4234002803 isParatext "false" @default.
• W4234002803 isRetracted "false" @default.
• W4234002803 workType "article" @default.